BENTSUR RON 4

What Happened

Ron Bentsur, a reported 10% owner of Nuvectis Pharma, bought 12,500 shares of Nuvectis common stock on June 30, 2026, at $20.00 per share, a total purchase value of $250,000. The purchase was made in the public offering announced June 29, 2026. This transaction is a straight purchase (code P), which retail investors often view as a more informative signal than routine insider sales.

Key Details

• Transaction date and price: June 30, 2026 — 12,500 shares @ $20.00 per share (total $250,000).
• Filing date: July 1, 2026 — appears to have been filed promptly after the transaction.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes:
  • F1: Purchase was in the public offering announced on June 29, 2026.
  • F2: Shares reported include restricted common stock.
• Transaction code: P (Purchase).

Context

• As a 10% owner, Bentsur is a large shareholder rather than necessarily an executive; purchases by large holders can reflect confidence or a desire to increase stake but do not by themselves explain motive.
• The purchase was part of a public offering rather than an open-market trade, which can affect timing and price availability.
• No options, gifts, or tax-withholding events are reported for this transaction.